We are live on ! Find out more
XPH icon

State Street SPDR S&P Pharmaceuticals ETF

72 hedge funds and large institutions have $115M invested in State Street SPDR S&P Pharmaceuticals ETF in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 19

1% less funds holding

Funds holding: 73 → 72 (-1)

3.45% less ownership

Funds ownership: 55.18% → 51.73% (-3.4%)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

31% less call options, than puts

Call options by funds: $957K | Put options by funds: $1.38M

43% less capital inflows, than outflows

Capital inflows: $15M | Capital outflows: $26.5M

Holders
72
Holders Change
-1
Holders Change %
-1.37%
% of All Funds
1.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
23
Reduced
19
Closed
10
Calls
$957​K
Puts
$1.38​M
Net Calls
-⁠$423​K
Net Calls Change
-⁠$65​K

XPH Hedge Fund Activity: Q1 2024 in Review

72 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q1 2024, worth a combined $115M — down 5.6% from $122M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of XPH and 8 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 23 added.

The largest buyer was Kingsview Wealth Management, adding an estimated $4.99M. The largest seller was Bank of America, cutting an estimated $9.21M.

  • 72 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q1 2024, down from 73 in Q4 2023.
  • Funds reported $115M of State Street SPDR S&P Pharmaceuticals ETF stock for Q1 2024, down 5.6% quarter-over-quarter.
  • 8 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q1 2024 and 10 closed out, a net change of -2 holders.
  • The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q1 2024 was Kingsview Wealth Management, an estimated $4.99M added.
  • The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q1 2024 was Bank of America, an estimated $9.21M sold.

Based on aggregated 13F filings for Q1 2024.